Doxapram Administration on Diaphragmatic Excursion in Mechanically Ventilated Patients With Chronic Obstructive Pulmonary Disease Undergoing Spontaneous Breathing Trial

Cairo University35 enrolled

Overview

Researchers aim to evaluate the impact of doxapram administration on diaphragmatic excursion in chronic obstructive pulmonary disease (COPD) patients undergoing spontaneous breathing trial

doxapram will be administered intravenously (IV) during spontaneous breathing trial. diaphragmatic excursion will be evaluated by an expert in respiratory muscle ultrasound

Study Type

OBSERVATIONAL

Enrollment

Conditions

COPD Mechanical Ventilation Weaning From Mechanical Ventilation

Interventions

DoxapramDRUG

Doxapram will be given as 1.5 mg/kg will be given 10 minutes after the initiation of SBT

Eligibility

Sex: ALLMin age: 20 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with moderate to severe chronic obstructive pulmonary disease undergoing spontaneous breathing trial Exclusion Criteria: * Refusal Allergy to doxapram neuromuscular disorders inability to evaluate the diaphragm

Locations (1)

Cairo University

Cairo, Cairo Governorate, Egypt

RECRUITING

Outcomes

Primary Outcomes

• Diaphragmatic excursion in mm

Time frame: before and 10 minutes after doxappram

Secondary Outcomes

Arterial blood gases

Time frame: before and 10 minutes after doxapram

Respiratory rate

Time frame: before and 10 minutes after doxapram

Central Contacts

Mina Helmy, MD

CONTACT

+201007174836 dr_mina20002010@yahoo.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.